Achilles Therapeutics ( (ACHL) ) has shared an announcement.
On February 28, 2025, Achilles Therapeutics announced its intention to voluntarily delist its American Depositary Shares from Nasdaq and deregister them from the SEC, with the delisting expected to be effective on March 20, 2025. This decision is part of a broader plan to commence a members’ voluntary liquidation, pending shareholder approval at a General Meeting on March 20, 2025, and will result in the suspension of the company’s obligation to file periodic reports with the SEC.
More about Achilles Therapeutics
Achilles Therapeutics is a company operating in the biotechnology industry, focusing on developing personalized cancer immunotherapies. The company is primarily engaged in creating innovative treatments targeting specific cancer mutations, aiming to provide tailored therapeutic solutions.
YTD Price Performance: 21.93%
Average Trading Volume: 818,363
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $57.13M
Find detailed analytics on ACHL stock on TipRanks’ Stock Analysis page.